Biotechnology
MedAlliance Acquired by Cordis for up to USD 1.135 Billion
GENEVA, Switzerland, Oct. 2, 2023 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has been acquired by Cordis for a 2022 investment of$35M and a 2023 upfront closing payment of $200M, together with regulatory achievement milestones of up to$125M and commercial milestones of up ...
2023-10-02 20:27
7735
ZEISS and Boehringer Ingelheim join forces to develop early detection of eye diseases and prevent vision loss
JENA, Deutschland and INGELHEIM, Deutschland, Oct. 2, 2023 /PRNewswire/ -- ZEISS Medical Technology and Boehringer Ingelheim announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vis...
2023-10-02 20:00
1517
SIBIONICS to Make Debut at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
SHENZHEN, China, Oct. 2, 2023 /PRNewswire/ -- The 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to take place from October 2nd to 6th, 2023, in Hamburg, Germany. Making its debut at this prestigious event, Shenzhen Sibionics Technology Co., Ltd. (hereinaft...
2023-10-02 16:24
2593
MedAlliance Acquired by Cordis for USD 1.135 Billion
GENEVA, Oct. 2, 2023 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has been acquired by Cordis for a 2022 investment of$35M and a 2023 upfront closing payment of$200M, together with regulatory achievement milestones of up to$125M and commercial milestones of up to $775M throu...
2023-10-02 11:44
2385
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
WUXI, China, Oct. 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner, Amicus Therapeutics ("Amicus") (Nasdaq: FOLD), on receiving U.S. FDA's approval for Pombili...
2023-10-02 08:30
1393
Akeso and RemeGen Collaborate on Clinical Study Exploring the Potential of PD-1/CTLA-4 Bispecific Antibody with HER-2 ADC Combination Therapy in Gastric Cancer
HONG KONG, Sept. 29, 2023 /PRNewswire/ -- On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/09995.HK) to advance the development of Akeso's globally first PD-1/CTLA-4 bispecific antibody, cadonilimab ...
2023-09-29 20:00
2882
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep. BNC210 was well-tolerated with a safety prof...
2023-09-29 12:13
2192
Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
HANGZHOU and SHAOXING, China, Sept. 29, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces positive interim data from the Phase IIb expansion cohort (the "Expansion Cohort") of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) for functional cure of ch...
2023-09-29 08:10
2621
Origin Agritech Limited Partners with Strategic Investor Relations, LLC to Support its Corporate Communications and Investor Relations Efforts
BEIJING, Sept. 28, 2023 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced that it has retained Strategic Investor Relations, LLC. ("SIR"), a leading boutique investor relations firm. This collaborati...
2023-09-28 23:34
1828
SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
CHENGDU, China, Sept. 28, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a partnership with The Structural Genomics Consortium ("SGC"), a public-private partnership that supports the discovery of new medi...
2023-09-28 21:30
1567
ProfoundBio Announces Upcoming Scientific Presentations at SITC 2023
SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate (ADC) therapeutics for cancer, announced four upcoming poster presentations on its ADC platform and lead clinical assets, rinatabart sesutecan (...
2023-09-28 20:00
2222
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor
SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH) , an innovative biopharmaceutical company with entire industry chain, announced the first patient was dosed in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D code: 9MW2821) in combination with PD-1 inhibitor for the treatm...
2023-09-28 20:00
1398
IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
82.4% of patients without prior CAR-T achieving Complete Response (CR) or better SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 28, 2023 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and ant...
2023-09-28 18:09
1527
BIOHK2023 LEAVES A MARK ON BIOTECH COMMUNITY: MUST-KNOW HIGHLIGHTS
HONG KONG, Sept. 28, 2023 /PRNewswire/ -- The journey of BIOHK2023 began with an unforgettable opening ceremony on day one, welcoming theNobel Trust Foundation, Dr. Michael Nobel and delivering a noteworthy speech by Mr. Peter Nobel. BIOHK had the privilege of hosting distinguished doctors, profe...
2023-09-28 10:00
2465
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China
WUXI, China, Sept. 27, 2023 /PRNewswire/ -- September 25th, 2023, BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity's BC3402, a monoclonal antibody (mAb) targeting the T cell immunoglobulin and muci...
2023-09-28 09:46
1998
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting
SHANGHAI and HONG KONG, Sept. 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for canc...
2023-09-28 08:30
1978
Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients
SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Everest Medicines
2023-09-28 07:38
2081
Lunit to Reveal 6 Abstracts at the SITC 2023 Annual Meeting
- Lunit's 6 posters unveil new tumor microenvironment insights and the predictive power of Lunit SCOPE across diverse cancer types at SITC 2023 SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeu...
2023-09-27 22:03
1672
OBiO has launched its state-of-the-art GMP production facility Intelli-M to expedite innovative and advanced therapies to patients who are in need.
SHANGHAI, Sept. 27, 2023 /PRNewswire/ -- In Shanghai, China, on August, OBiO Technology, a prominent leader in the Cell and Gene Therapy (CGT) field and a Contract Development and Manufacturing Organization, proudly unveiled the official launch of its state-of-the-art GMP production facility, chr...
2023-09-27 21:00
1589
Remegen's Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis
YANTAI, China, Sept. 27, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
2023-09-27 09:30
3345
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7722
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7116